At a Glance
- Companies: Mabtech AB; Sai Life Sciences
- Location: Stockholm, Sweden (Mabtech); Boston, USA (Sai hub)
- Headline: Strategic collaboration agreement
- Focus area: EYRA platform for multiplex cytokine/phenotyping
- Next steps: Joint assay services and demonstrations
What happened?
Mabtech and Sai Life Sciences announced a strategic collaboration on 28 January 2026, establishing Sai’s Boston laboratory as a US execution hub for Mabtech’s EYRA platform. The partnership enables joint delivery of high-sensitivity multiplex immunology assays, including cytokine profiling and phenotyping workflows.
Why does it matter?
EYRA overcomes limitations of flow cytometry and plate-based systems by enabling flow-free, confocal imaging of up to 40 bead populations with automation-ready quantitative outputs. Accelerates immune profiling for biopharma in immuno-oncology, vaccines, inflammation and cell therapy, streamlining hypothesis-to-decision timelines.
Who’s behind it?
Mabtech develops immunoassay tools like ELISpot/FluoroSpot/EYRAplex; Sai Life Sciences provides integrated discovery-to-commercial services across US/India/Europe sites.
How was it achieved?
EYRA uses confocal microscopy for bead-based multiplexing with Opal software generating concentrations from PE signals, producing Excel-ready data with standard curves. Collaboration includes co-branded pilots, thought leadership and BD integration at Sai Boston.
What’s next?
Joint service rollout of EYRA panels/custom assays; expanded access to scalable workflows supporting translational research.
What are people saying?
Partnership positions “next-generation immune profiling capabilities” for US clients seeking rapid, precise data.